Evidence map›Paper›PMID 37513710›Full record

ArticlePathogens (Basel, Switzerland)2023

Evaluation of Four Adjuvant Combinations, IVAX-1, IVAX-2, CpG-1826+Montanide ISA 720 VG and CpG-1018+Montanide ISA 720 VG, for Safety and for Their Ability to Elicit Protective Immune Responses in Mice against a Respiratory Challenge with

Sukumar Pal, Anatoli Slepenkin, Jiin Felgner, D Huw Davies, Philip Felgner, Luis M de la Maza

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pathogens (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Structural Assessment ofVaccines · 2024
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Sukumar PalDepartment of Pathology and Laboratory Medicine, University of California, Irvine, CA 92697, USA.
Anatoli SlepenkinDepartment of Pathology and Laboratory Medicine, University of California, Irvine, CA 92697, USA.
Jiin FelgnerVaccine Research and Development Center, Department of Physiology and Biophysics, University of California, Irvine, CA 92697, USA.
D Huw DaviesVaccine Research and Development Center, Department of Physiology and Biophysics, University of California, Irvine, CA 92697, USA.
Philip FelgnerVaccine Research and Development Center, Department of Physiology and Biophysics, University of California, Irvine, CA 92697, USA.
Luis M de la MazaDepartment of Pathology and Laboratory Medicine, University of California, Irvine, CA 92697, USA.

Funding

IMMUNOPATHOLOGY OF TUBAL INFERTILITYR01AI032248 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI DE LA MAZA, LUIS M · 1993 to 2007
$2.6M
Defining molecular mechanisms of combination adjuvants: a systems immunology, transcriptomics and imaging approachU01AI160397 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI DAVIES, DAVID HUW · 2021 to 2024
$2.4M
Recombinant C. trachomatis vaccineR01AI067888 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI DE LA MAZA, LUIS M · 2007 to 2011
$1.9M
NIAID NIH HHS R01 AI032248NIAID NIH HHS R01 AI067888NIAID NIH HHS U01 AI160397
6 · The paper itself

Abstract

There is an urgent need to produce a vaccine for

Indexed as

adjuvant combinationsChlamydia muridarumChlamydia trachomatismajor outer membrane proteinmicevaccine

Identifiers

PMID37513710
PMCPMC10383793

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.